长非编码RNA揭示了儿童喘的重要途径:未来的视角
Vahid Goodarzi1, Shadi Nouri2, Zohre Saleh Nassaj3
1Department of Anesthesiology, Rasoul-Akram Medical Center, Iran University of Medical Sciences (IUMS), Tehran, Iran.
Journal of molecular histology
|August 3, 2023
概括
长非编码RNAs (lncRNAs) 与儿童喘病因发生有关. lncRNAs的失调影响呼吸道炎症,增殖和重塑,提供潜在的治疗点.
科学领域:
- 儿科呼吸系统医学 儿科呼吸系统医学
- 分子生物学分子生物学
- 基因组学就是基因组学.
背景情况:
- 儿童喘是一种慢性呼吸道炎症疾病,其特点是呼吸道重塑.
- 儿童喘背后的确切的病原机制仍然不完全理解.
- 长非编码RNAs (lncRNAs) 正在成为喘发病的关键调节者.
研究的目的:
- 审查当前对儿童喘中lncRNA失调的理解.
- 阐明 lncRNAs 在呼吸道炎症,细胞增殖和重塑中的作用.
- 为了指导儿童喘的未来研究方向.
主要方法:
- 儿童喘的转录组分析.
- 关于喘中的lncRNA功能的现有文献的综述.
- 通过 lncRNAs 调节的信号通路的分析.
主要成果:
- lncRNAs调节瘤基因活动 (例如c-Myc,Akt,ERK) 和信号通路 (例如MAPK,NF-κB,Wnt).
- lncRNA与TGFβ,β-catenin和SKP2等通路相互作用,有助于交叉通话.
- 特定的lncRNAs通过miRNA海绵激活Wnt和Notch1通路,促进细胞增殖.
结论:
- lncRNA失调在儿童喘的发病过程中起着重要作用.
- lncRNAs参与关键过程,包括炎症,细胞增殖和呼吸道重塑.
- 针对 lncRNAs 是未来喘治疗的有希望的途径.
相关概念视频
lncRNA - Long Non-coding RNAs
8.6K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.6K
Asthma-II: Pathophysiology and Classification
2.7K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.7K
Asthma: Pathogenesis and Management
446
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
446
Asthma-I: Introduction
2.7K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
2.7K
Types of RNA
5.9K
Three main types of RNA are involved in protein synthesis: messenger RNA (mRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA). These RNAs perform diverse functions and can be broadly classified as protein-coding or non-coding RNA. Non-coding RNAs play important roles in regulating gene expression in response to developmental and environmental changes. Non-coding RNAs in prokaryotes can be manipulated to develop more effective antibacterial drugs for human or animal use.
RNA Performs Diverse...
RNA Performs Diverse...
5.9K
Antiasthma Drugs: Leukotriene Modifiers
357
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
357


